Pivotal-Point Tracking Merck & Co. (MRK): All-Time High After Phase 3 Success - Pharma Giant Benefits from Moderna mRNA Cancer Vaccine
Reading Time: 1 minute
Merck & Co. is one of the leading pharmaceutical companies worldwide, focusing on oncology, vaccines, and animal health. Its most well-known blockbuster is the immunotherapy Keytruda. On August 19, the company reported significant Phase 3 successes for an mRNA cancer vaccine against melanoma developed in collaboration with Moderna. The study data alleviates concerns about expiring patents and underscores the potential of the development portfolio. Merck benefits primarily from two key drivers. First, the combination of Keytruda with mRNA technology...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
